Cargando…

Definitive hyperfractionated, accelerated proton reirradiation for patients with pelvic malignancies

INTRODUCTION: Pelvic reirradiation (re-RT) presents challenges due to concerns for late toxicity to tissues-at-risk including pelvic bone marrow (PBM). We routinely utilize a hyperfractionated, accelerated re-RT for recurrent rectal or anal cancer in the setting of prior radiation. We hypothesized t...

Descripción completa

Detalles Bibliográficos
Autores principales: Moningi, Shalini, Ludmir, Ethan B., Polamraju, Praveen, Williamson, Tyler, Melkun, Marcella M., Herman, Joseph D., Krishnan, Sunil, Koay, Eugene J., Koong, Albert C., Minsky, Bruce D., Smith, Grace L., Taniguchi, Cullen, Das, Prajnan, Holliday, Emma B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6734102/
https://www.ncbi.nlm.nih.gov/pubmed/31517071
http://dx.doi.org/10.1016/j.ctro.2019.08.004
_version_ 1783450085622808576
author Moningi, Shalini
Ludmir, Ethan B.
Polamraju, Praveen
Williamson, Tyler
Melkun, Marcella M.
Herman, Joseph D.
Krishnan, Sunil
Koay, Eugene J.
Koong, Albert C.
Minsky, Bruce D.
Smith, Grace L.
Taniguchi, Cullen
Das, Prajnan
Holliday, Emma B.
author_facet Moningi, Shalini
Ludmir, Ethan B.
Polamraju, Praveen
Williamson, Tyler
Melkun, Marcella M.
Herman, Joseph D.
Krishnan, Sunil
Koay, Eugene J.
Koong, Albert C.
Minsky, Bruce D.
Smith, Grace L.
Taniguchi, Cullen
Das, Prajnan
Holliday, Emma B.
author_sort Moningi, Shalini
collection PubMed
description INTRODUCTION: Pelvic reirradiation (re-RT) presents challenges due to concerns for late toxicity to tissues-at-risk including pelvic bone marrow (PBM). We routinely utilize a hyperfractionated, accelerated re-RT for recurrent rectal or anal cancer in the setting of prior radiation. We hypothesized that proton beam radiation (PBR) is uniquely suited to limit doses to pelvic non-target tissues better than photon-based approaches. MATERIALS AND METHODS: All patients who received hyperfractionated, accelerated PBR re-RT to the pelvis from 2007 to 2017 were identified. Re-RT was delivered twice daily with a 6 h minimum interfraction interval at 1.5 Gray Relative Biological Effectiveness (Gy(RBE)) per fraction to a total dose of 39–45 Gy(RBE). Concurrent chemotherapy was given to all patients. Comparison photon plans were generated for dosimetric analysis. Dosimetric parameters compared using a matched-pair analysis and the Wilcoxon signed-rank test. Survival analysis was performed Kaplan Meier curves. RESULTS: Fifteen patients were identified, with a median prior pelvic RT dose of 50.4 Gy (range 25–80 Gy). Median time between the initial RT and PBRT re-RT was 4.7 years (range 1.0–36.1 years). In comparison to corresponding photon re-RT plans, PBR re-RT plans had lower mean PBM dose, and lower volume of PBM getting 5 Gy, 10 Gy, 20 Gy, and 30 Gy (p < 0.001, p < 0.001, p < 0.001, and p = 0.033, respectively). With median 13.9 months follow-up after PBR re-RT, five patients had developed local recurrences, and four patients had developed distant metastases. One-year overall survival following PBR re-RT was 67.5% and one-year progression free survival was 58.7%. No patients developed acute or late Grade 4 toxicity. CONCLUSION: PBR re-RT affords improved sparing of PBM compared with photon-based re-RT. Clinically, PBR re-RT is well-tolerated. However, given modest control rates with definitive re-RT without subsequent surgical resection, a multidisciplinary approach should be favored in this setting when feasible.
format Online
Article
Text
id pubmed-6734102
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-67341022019-09-12 Definitive hyperfractionated, accelerated proton reirradiation for patients with pelvic malignancies Moningi, Shalini Ludmir, Ethan B. Polamraju, Praveen Williamson, Tyler Melkun, Marcella M. Herman, Joseph D. Krishnan, Sunil Koay, Eugene J. Koong, Albert C. Minsky, Bruce D. Smith, Grace L. Taniguchi, Cullen Das, Prajnan Holliday, Emma B. Clin Transl Radiat Oncol Article INTRODUCTION: Pelvic reirradiation (re-RT) presents challenges due to concerns for late toxicity to tissues-at-risk including pelvic bone marrow (PBM). We routinely utilize a hyperfractionated, accelerated re-RT for recurrent rectal or anal cancer in the setting of prior radiation. We hypothesized that proton beam radiation (PBR) is uniquely suited to limit doses to pelvic non-target tissues better than photon-based approaches. MATERIALS AND METHODS: All patients who received hyperfractionated, accelerated PBR re-RT to the pelvis from 2007 to 2017 were identified. Re-RT was delivered twice daily with a 6 h minimum interfraction interval at 1.5 Gray Relative Biological Effectiveness (Gy(RBE)) per fraction to a total dose of 39–45 Gy(RBE). Concurrent chemotherapy was given to all patients. Comparison photon plans were generated for dosimetric analysis. Dosimetric parameters compared using a matched-pair analysis and the Wilcoxon signed-rank test. Survival analysis was performed Kaplan Meier curves. RESULTS: Fifteen patients were identified, with a median prior pelvic RT dose of 50.4 Gy (range 25–80 Gy). Median time between the initial RT and PBRT re-RT was 4.7 years (range 1.0–36.1 years). In comparison to corresponding photon re-RT plans, PBR re-RT plans had lower mean PBM dose, and lower volume of PBM getting 5 Gy, 10 Gy, 20 Gy, and 30 Gy (p < 0.001, p < 0.001, p < 0.001, and p = 0.033, respectively). With median 13.9 months follow-up after PBR re-RT, five patients had developed local recurrences, and four patients had developed distant metastases. One-year overall survival following PBR re-RT was 67.5% and one-year progression free survival was 58.7%. No patients developed acute or late Grade 4 toxicity. CONCLUSION: PBR re-RT affords improved sparing of PBM compared with photon-based re-RT. Clinically, PBR re-RT is well-tolerated. However, given modest control rates with definitive re-RT without subsequent surgical resection, a multidisciplinary approach should be favored in this setting when feasible. Elsevier 2019-08-27 /pmc/articles/PMC6734102/ /pubmed/31517071 http://dx.doi.org/10.1016/j.ctro.2019.08.004 Text en © 2019 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Article
Moningi, Shalini
Ludmir, Ethan B.
Polamraju, Praveen
Williamson, Tyler
Melkun, Marcella M.
Herman, Joseph D.
Krishnan, Sunil
Koay, Eugene J.
Koong, Albert C.
Minsky, Bruce D.
Smith, Grace L.
Taniguchi, Cullen
Das, Prajnan
Holliday, Emma B.
Definitive hyperfractionated, accelerated proton reirradiation for patients with pelvic malignancies
title Definitive hyperfractionated, accelerated proton reirradiation for patients with pelvic malignancies
title_full Definitive hyperfractionated, accelerated proton reirradiation for patients with pelvic malignancies
title_fullStr Definitive hyperfractionated, accelerated proton reirradiation for patients with pelvic malignancies
title_full_unstemmed Definitive hyperfractionated, accelerated proton reirradiation for patients with pelvic malignancies
title_short Definitive hyperfractionated, accelerated proton reirradiation for patients with pelvic malignancies
title_sort definitive hyperfractionated, accelerated proton reirradiation for patients with pelvic malignancies
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6734102/
https://www.ncbi.nlm.nih.gov/pubmed/31517071
http://dx.doi.org/10.1016/j.ctro.2019.08.004
work_keys_str_mv AT moningishalini definitivehyperfractionatedacceleratedprotonreirradiationforpatientswithpelvicmalignancies
AT ludmirethanb definitivehyperfractionatedacceleratedprotonreirradiationforpatientswithpelvicmalignancies
AT polamrajupraveen definitivehyperfractionatedacceleratedprotonreirradiationforpatientswithpelvicmalignancies
AT williamsontyler definitivehyperfractionatedacceleratedprotonreirradiationforpatientswithpelvicmalignancies
AT melkunmarcellam definitivehyperfractionatedacceleratedprotonreirradiationforpatientswithpelvicmalignancies
AT hermanjosephd definitivehyperfractionatedacceleratedprotonreirradiationforpatientswithpelvicmalignancies
AT krishnansunil definitivehyperfractionatedacceleratedprotonreirradiationforpatientswithpelvicmalignancies
AT koayeugenej definitivehyperfractionatedacceleratedprotonreirradiationforpatientswithpelvicmalignancies
AT koongalbertc definitivehyperfractionatedacceleratedprotonreirradiationforpatientswithpelvicmalignancies
AT minskybruced definitivehyperfractionatedacceleratedprotonreirradiationforpatientswithpelvicmalignancies
AT smithgracel definitivehyperfractionatedacceleratedprotonreirradiationforpatientswithpelvicmalignancies
AT taniguchicullen definitivehyperfractionatedacceleratedprotonreirradiationforpatientswithpelvicmalignancies
AT dasprajnan definitivehyperfractionatedacceleratedprotonreirradiationforpatientswithpelvicmalignancies
AT hollidayemmab definitivehyperfractionatedacceleratedprotonreirradiationforpatientswithpelvicmalignancies